Stem Cell Therapy for PSP in India

EDITORIAL GOVERNANCE & MEDICAL REVIEW

Clinical E-E-A-T Verified

✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
✓
Medically Reviewed By: Dr. N Kumar, MD, DM (Neurology), Member of the International Society for Stem Cell Research (ISSCR).
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
✓
Clinical Governance Protocol: SOP-PSP-07 (Investigational Cellular Protocol)

• Last Clinical Review: September 2026 | Next Scheduled Re-Audit: March 2027

View Editorial Standards →

Condition Overview & Research Scope

Clinical Overview & Biological Mechanism

Pathology, cellular action of Mesenchymal Stem Cells (MSCs), and investigational intent

The Pathology:

Progressive Supranuclear Palsy (PSP) is an atypical neurodegenerative parkinsonian tauopathy (4R-tau) characterized by abnormal hyperphosphorylated tau protein accumulation, microglial activation, and progressive neuronal loss in the subthalamic nucleus, substantia nigra, and brainstem.

The Cellular Mechanism:

Umbilical cord-derived Mesenchymal Stem Cells (UC-MSCs) act primarily via secretome-mediated paracrine signaling and neuro-immunomodulation:

Downregulate chronically activated pro-inflammatory M1 microglia and astrocytes, dampening neurotoxic inflammatory cytokines (TNF-$\alpha$, IL-1$\beta$, IL-6).
Release neurotrophic secretomes (such as BDNF, GDNF, and VEGF) that support surviving neuronal circuits and stimulate local microvascular perfusion.
Reduce oxidative stress in deep subcortical brain structures.

Investigational Intent:

This is an adjunctive, non-curative cellular intervention. It does not dissolve intracellular neurofibrillary tau tangles or replace deceased midbrain neurons; rather, it aims to reduce secondary neuroinflammation, stabilize functional decline, and support motor independence alongside standard neuro-rehabilitation.

Clinical Eligibility & Selection Criteria

Candidate Screening & Safety Triage

Inclusion criteria, absolute safety exclusions, and pre-arrival diagnostic clearance

Eligible Profiles for Evaluation:

Clinically probable or possible PSP (Richardson's syndrome or PSP-Parkinsonism variants) verified through clinical exams, brain MRI (demonstrating midbrain atrophy/hummingbird sign), or DAT scans.
Presence of axial rigidity, postural instability, early backward falls, or vertical supranuclear gaze palsy with poor or transient response to levodopa.
Baseline forced vital capacity (FVC) $\ge 60\%$ of predicted value; clinically cleared for commercial air travel with an accompanying caregiver.

Absolute Exclusion Criteria (Non-Candidates):

Severe advanced dysphagia with active aspiration risk or recurrent aspiration pneumonia (requires urgent gastroenterological feeding tube placement, not elective outpatient cell therapy).
End-stage bed-bound state, profound cognitive impairment, or inability to communicate basic needs.
Active systemic infection, unmanaged malignancy, or acute cardiovascular instability.

Pre-Arrival Medical Clearance:

International candidates must submit recent brain MRI scans, formal swallowing evaluations (FEES/VFSS), cognitive scoring (MoCA/MMSE), spirometry reports, and video recordings of gait and eye movements for review by our neurology board before travel booking.

Targeted Clinical Objectives

Potential Improvements & Realistic Clinical Boundaries

Reported functional goals alongside documented non-responder rates and realistic limits

Biological responses vary widely by disease stage and individual neuro-inflammatory profiles. Results cannot be guaranteed, and cellular therapy is strictly adjunctive to standard palliative and neurological care.

Axial Stability & Posture: Mild-to-moderate stabilization of core rigidity, helping reduce sudden backward loss of balance and fall frequency.

Motor Control & Transfers: Improved ease with sit-to-stand transfers and bed mobility when combined with specialized vestibular physiotherapy.

Vocal Clarity & Speech: Modest reduction in spastic dysarthria and vocal strain during sustained conversations.

Swallowing Transit (Early-Stage Dysphagia): Decreased mealtime choking episodes and improved bolus control when combined with speech therapy precautions.

Fatigue Resistance & Alertness: Reductions in daytime somnolence and chronic neuro-exhaustion.

Documented Clinical Realities:

No Tau Clearance: MSCs cannot clear existing neurofibrillary tau tangles or reverse established midbrain atrophy.

Supranuclear Gaze Limitation: Complete vertical gaze paralysis rarely shows significant restoration.

Non-Responder Rate: An estimated 25–35% of patients experience minimal functional response, and underlying neurodegenerative progression may continue.

Safety Profile & Governance

Clinical Safety Profile & Anticipated Adverse Reactions

Anticipated transient reactions, procedural safeguards, and long-term surveillance

Clinical-grade, unmanipulated allogeneic MSCs maintain a documented safety profile, but patients and caregivers should be aware of potential transient reactions:

Common & Transient (Days 1–3):

Mild post-infusion low-grade fever ($< 38^\circ\text{C}$ / $100.4^\circ\text{F}$), temporary fatigue, mild headache, or minor cannula site tenderness.

Rare Risks:

Allergic hypersensitivity reactions or blood pressure fluctuations (infusions are administered under continuous bedside cardiac telemetry and vital sign tracking).

Patient Safeguards: Fall-prevention setups, continuous pulse oximetry, and immediate access to full tertiary critical-care backup during every session.

Treatment Schedule & Roadmap

Step-by-Step Treatment Schedule & In-Hospital Workflow

Structured clinical itinerary during your stay in India (5 to 7 Days)

Total Program Length: 4 to 6 days on an outpatient hospital daycare and monitored recovery basis.

Day 1 (Comprehensive Hospital Workup):

In-person evaluation by a movement disorder neurologist; baseline PSP Rating Scale (PSPRS) and Berg Balance Scale scoring.

Safety profile validation: CBC, renal and liver panels, cardiac biomarkers, baseline spirometry, and bedside swallowing evaluation.

None:

Days 2–3 (Cell Delivery & Supervised Neuro-Rehabilitation):

Intravenous (IV) infusion of certified, viable UC-MSCs in saline suspension under continuous vital monitoring.

Supervised neuro-physiotherapy: balance re-training, fall-prevention strategies, assistive device optimization, and diaphragmatic breathing coaching.

Days 4–5 (Post-Infusion Assessment & Rest):

Clinical review of vital stability, post-procedure tolerance check, and issuance of a personalized home-rehabilitation protocol.

Day 6 (Discharge & Return Travel Clearance):

Final neurological review and issuance of fit-to-fly documentation.

Longitudinal Remote Follow-Up:

Scheduled telemedicine consultations at Months 1, 3, 6, and 12, coordinated directly with your domestic neurologist.

Strategic Hospital Advantages

Why Receive Care at Our Specialized Center in India?

Super-specialist clinical oversight, cGMP cleanroom facilities, and high cell viability

Movement Disorder Specialists: Supervised directly by post-doctoral DM/DNB Neurologists and cellular biologists.

Cell Purity & Traceability:

Umbilical cord-derived MSCs sourced from screened full-term donors, processed in ISO Class 5 cleanrooms, and verified for high viability ($>85\%$), sterility, negative mycoplasma, endotoxin safety, and flow cytometry immunophenotyping (CD73+, CD90+, CD105+ / CD34-, CD45-, HLA-DR-).

Transparent Pricing Scope:

Standard comprehensive packages range from $5,200 to $7,800 USD (inclusive of cellular biologicals, hospital daycare fees, physician consultations, and baseline routine tests). Detailed written estimates are provided prior to travel.

Estimated Costs & Package Inclusions

Treatment Costs & Comparative Package Inclusions

Transparent international pricing with comprehensive hospital, cellular, and logistical inclusions

Package Range Transparent Pricing

$5,200 – $7,800 USD

(Comprehensive package covering targeted UC-MSCs, procedural suites, specialist fees, and 12-month monitoring).

Clinical Objective Investigational Care

Progressive Supranuclear Palsy (PSP) Care

(Administered under strict ISO Class 5 cleanroom standards and institutional ethics oversight).

Country / Region	Typical Package Range	Waiting Period	Clinical Accreditation
India (Our Specialized Centers)	$5,200 – $7,800 USD	1 – 2 Weeks	NABH / JCI Accredited
United States	$35,000 – $65,000 USD	3 – 6 Months	Clinical Trial Gated
Germany & Switzerland	$28,000 – $55,000 USD	2 – 4 Months	Private Specialty Only
Panama / Mexico	$18,000 – $32,000 USD	2 – 4 Weeks	Variable Regional

Package Inclusions:

Pre-procedure specialty diagnostics, baseline scans, and multidisciplinary doctor evaluations.

cGMP cleanroom certified cellular harvesting, flow-cytometry viability testing (>85%), and procedural suite fees.

Government Medical Visa (MED Visa) invitation assistance and complimentary chauffeured airport transfers.

Dedicated bilingual case coordinator and 12 months of structured remote post-procedure monitoring.

International Patient Services

Dedicated Support for International Patients & Families

Full medical concierge care, government visa assistance, and airport transit

Medical Visa (MED) Processing:

Official hospital visa invitation letters issued within 24–48 hours for the patient and accompanying caregiver (with FRRO guidance).

Dedicated Case Coordinator:

A single English-speaking coordinator manages appointments, medical records, and hospital logistics.

Airport & Ground Transit:

Complimentary private airport pick-up/drop-off with dedicated wheelchair-accessible transport.

Language & Dietary Care:

Multi-language translators (Arabic, Russian, French) and access to customized meals (Halal, Vegetarian, Continental).

Travel & Logistics

Logistics & Accessible Accommodation

Daycare outpatient protocol, nearby wheelchair-accessible partner lodging, and daily transfers

Daycare Model:

Treatments occur in morning sessions, allowing the patient to rest in private quarters each afternoon to avoid sensory and motor fatigue.

Fall-Safe Lodging: Partner 4-star hotels and serviced apartments located within 10–15 minutes of the hospital, featuring step-free access, elevators, roll-in showers, and grab bars.

Direct Daily Commute:

Arranged transfers between local lodging and the medical center to prevent transit fatigue.

Regulatory & Ethics

Regulatory Disclosures & Ethical Declarations

Statutory compliance under ICMR-DBT National Guidelines and vital medication advisories

Investigational Therapy Notice:

Cell-based therapies for Progressive Supranuclear Palsy are categorized as investigational cellular treatments under the National Guidelines for Stem Cell Research published by the Indian Council of Medical Research (ICMR) and Central Drugs Standard Control Organisation (CDSCO). They are not marketed as an approved routine standard of care or a definitive cure.

Medication Continuity Warning: Patients must never discontinue or alter their standard prescription medications (e.g., Levodopa, Amantadine, CoQ10) or swallowing precautions without express authorization from their primary treating neurologist.

Ethical Standards:

All biological procurement complies with informed maternal consent, donor screening, and statutory bioethics standards.

Scientific Citations

Peer-Reviewed Clinical Literature & Scientific Context

Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms

Scientific Notice on Study Types:

Scientific Scope & Route of Delivery Note: References 1 and 2 report on early human clinical trials evaluating autologous MSCs (including bone marrow and adipose tissue sources, some utilizing intrathecal routes). Reference 3 reviews mesenchymal stem cell secretome mechanisms in neurodegenerative models. Reference 4 describes the international clinical trial framework for evaluating disease-modifying agents in PSP. These references are provided to support informed discussions between patients, families, and their home neurologists.

Adipose-Derived Mesenchymal Stem Cells in Progressive Supranuclear Palsy (PMC / Case Report)

PMC12636885 ↗

Mesenchymal stem cells in neurological disorders: mechanisms and therapeutic potential. Stem Cell Res Ther / PMC, 2025; PMCID: PMC12636885.

Clinical Context: Reviews secretome composition across tissue sources and details how neurotrophic factors and immunomodulatory cytokines protect neural networks against neurodegenerative stress.

The Progressive Supranuclear Palsy Clinical Trial Platform (ClinicalTrials.gov / NIH)

The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) for neurodegenerative evaluation. NIH ClinicalTrials.gov; NCT07173803.

Clinical Context: Outlines the international multi-center clinical platform evaluating novel neuroprotective and disease-modifying agents in PSP, highlighting standardized clinical rating scale endpoints (PSPRS, FIM).

Frequently Asked Questions

Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Progressive Supranuclear Palsy (PSP)

No, stem cell therapy is not recognized as a definitive or permanent cure. Under Indian Council of Medical Research (ICMR) and CDSCO clinical guidelines, cellular therapy for Progressive Supranuclear Palsy (PSP) is an investigational and supportive treatment. Its objective is to modulate pathogenic immune activity, release neurotrophic and cytoprotective paracrine factors, and slow down progression to improve quality of life under strict institutional ethics oversight.

Umbilical cord-derived Mesenchymal Stem Cells (UC-MSCs) act primarily through paracrine immunomodulation and secretome release. They downregulate pro-inflammatory cytokines, modulate hyperactive cytotoxic T-cells, inhibit excessive fibrotic scarring, and secrete restorative growth factors (such as HGF, VEGF, BDNF, and IL-10) that support microvascular circulation and cellular tissue survival.

The comprehensive outpatient daycare protocol requires approximately 5 to 7 Days in India. Day 1 involves baseline diagnostic blood panels, imaging, and specialty evaluation by a Neurology & Neurodegenerative Disorders board. Days 2 and 3 include monitored cellular infusion (Targeted Intrathecal & Systemic IV Cellular Administration) under vital telemetry, followed by post-procedure observation, mobility guidance, and fit-to-fly clearance on Day 7.

Certified cGMP-processed allogeneic UC-MSCs possess an established safety profile with zero risk of donor graft-versus-host disease (GvHD). Common transient reactions include self-limiting low-grade fever (< 38°C / 100.4°F), temporary fatigue, or mild injection-site soreness resolving within 24–48 hours. Patients undergo pre-infusion safety checks and continuous bedside monitoring.

Comprehensive international treatment packages range from $5,200 – $7,800 USD. This transparent pricing includes clinical-grade certified UC-MSC biologicals (flow-cytometry verified >85% viability), specialized hospital procedural suites, doctor consultations, routine baseline safety labs, medical visa (MED) invitation support, and 12 months of structured remote follow-up.

Before confirming medical travel, international patients must submit recent clinical diagnostic reports (specialty scans, blood chemistry, disease-specific antibody panels, or biopsy records) for preliminary evaluation by our medical board. Our clinical team reviews the records within 24 to 48 hours to confirm candidacy before issuing official visa invitation letters.

✓
Accreditations: NABH-Accredited Inpatient Tertiary Hospital | ISO Class 5 Cleanroom Processing
✓
Statutory Oversight: Institutional Committee for Stem Cell Research (IC-SCR) & Registered Institutional Ethics Committee (IEC)
✓
Regulatory Alignment: Conducted under the ICMR-DBT National Guidelines for Stem Cell Research (India)
✓
Direct International Triage:
WhatsApp / Phone: +91-7744005984

Email: contact@stemcelltherapyinindia.com

PARTNER HOSPITALS TREATING PROGRESSIVE SUPRANUCLEAR PALSY (PSP):

RELATED PROTOCOLS:

Category	Details	Cost
🏥 Medical Procedure Cellular processing & specialist fees	Standard Protocol	$4,200
🏨 Accommodation Private room near hospital	7 nights @ $35/night	$245
🍽 Meals & Nutrition Dietary plan for patient & companions	7 days × 2 person(s) @ $25/day	$350
🚗 Local Transfers & Visa	Ground handling & priority transit	$200
💎 Total Estimated Budget All-inclusive medical + logistics	Combined estimate for 7 days (2 travelers)	$4,995